(6R,7R)-7-(2-hydroxy-2-phenylacetamido)-8-oxo-3-({[1-(sulfomethyl)-1H-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

• ChemBase编号: 1162
• 分子式: C18H18N6O8S3
• 平均质量: 542.56592
• 单一同位素质量: 542.03482457
• SMILES: S1[C@H]2N(C(=O)[C@H]2NC(=O)C(O)c2ccccc2)C(=C(C1)CSc1n(nnn1)CS(=O)(=O)O)C(=O)O
• Canonical SMILES: O=C(C(c1ccccc1)O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1CS(=O)(=O)O
• InChI: InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13?,16-/m1/s1
• InChIKey: DYAIAHUQIPBDIP-UJBKNGIVSA-N

名称和登记号

名称

• IUPAC标准名: (6R,7R)-7-(2-hydroxy-2-phenylacetamido)-8-oxo-3-({[1-(sulfomethyl)-1H-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
• IUPAC传统名: monocef
• 商标名: Monocid; Praticef
• 别名: Cefonicido [inn-spanish]; Cefonicidum [inn-latin]; Cefonicid

登记号

• CAS号: 61270-58-4
• PubChem SID: 160964625
• PubChem CID: 43592

理论计算性质

JChem

• Acid pKa: -1.404536
• 质子受体: 11
• 质子供体: 4
• LogD (pH = 5.5): -5.733945
• LogD (pH = 7.4): -6.8324103
• Log P: -2.5153315
• 摩尔折射率: 136.5757 cm^3
• 极化性: 48.276943 Å^3
• 极化表面积: 204.91 Å^2
• 可自由旋转的化学键: 9
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: -0.71
• LOG S: -2.78
• 溶解度: 8.95e-01 g/l

详细说明

DrugBank - DB01328

• Drug Groups: approved
• Description: A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections. [PubChem]
• Indication: For the treatment of bacterial infections caused by susceptible microorganisms.
• Pharmacology: Cefonicid is a second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.
• Affected Organisms: Enteric bacteria and other eubacteria
• Biotransformation: Not metabolized.
• Half Life: 4.5 hours
• Protein Binding: 98% bound to plasma proteins.